Monash University update on Ivermectin trial
As indicated in our August statement on the Monash BDI news page, Dr Kylie Wagstaff has been working to establish a blinded and randomised clinical trial of Ivermectin.
The clinical trial has now commenced and has been set up as a placebo-controlled, double-blinded post-exposure prophylaxis trial.
Trial participants must be aged between 18 and 80 years of age, have been a close contact with a confirmed COVID-19 positive person within the previous 72 hours, and have tested negative to a RAT or PCR test.
Perhaps it will save Australia from the disaster that is coming this winter.
Trial results are expected late in 2022. The results of the trial will be written up and submitted to a relevant journal for peer review. We will update the progress via the BDI website.